Financial Data and Key Metrics Changes - Total revenues for 2025 reached $589 million, a 19.8% increase from $491.7 million in 2024, exceeding previous guidance [3][21] - Net product revenue for 2025 was $588.8 million, reflecting a 20.3% increase over 2024 [4][23] - GAAP net income for 2025 was $214.3 million, or $1.68 per diluted share, a 30.8% increase compared to $163.9 million in 2024 [24][23] - Non-GAAP net income for 2025 was $346.2 million, or $2.72 per diluted share, compared to $276.3 million, or $2.21 per diluted share in 2024 [24][25] Business Line Data and Key Metrics Changes - Firdapse generated $358.4 million in revenue for 2025, a 17% increase year-over-year [6][13] - AGAMREE achieved $117.1 million in revenue for 2025, representing a remarkable 154.3% year-over-year growth [8][17] - Fycompa generated $113.3 million in revenue for 2025, with expectations of $40 million to $45 million for 2026 due to generic competition [10][23] Market Data and Key Metrics Changes - The addressable market for LEMS is estimated to exceed $1 billion, with significant growth opportunities identified in both idiopathic and cancer-associated LEMS [7][16] - The addressable market for AGAMREE is also projected to be over $1 billion, with ongoing studies expected to enhance its market position [8][9] Company Strategy and Development Direction - The company aims to maximize the value of its commercial portfolio through personalized support for patients with rare diseases [3][32] - Strategic focus includes dual market expansion for Firdapse and deepening market penetration for AGAMREE [32] - The company is pursuing business development opportunities for differentiated rare disease products, with a focus on assets with peak sales potential of up to $500 million [11][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued growth, with 2026 revenue guidance set between $615 million and $645 million [4][22] - The company highlighted the importance of patient identification and market penetration as key drivers for future growth [6][39] - Management acknowledged the challenges posed by generic competition but remains optimistic about the long-term potential of its product portfolio [10][23] Other Important Information - The company ended 2025 with cash and cash equivalents of $709.2 million, up from $517.6 million at the end of 2024 [30][31] - Research and development expenses for 2025 were $12.7 million, with expectations for an increase in 2026 due to ongoing studies [28][29] Q&A Session Summary Question: Drivers of growth for 2026 guidance for Firdapse and AGAMREE - Management highlighted the significant pool of identified patients and increased RGCC testing as key growth drivers [36][37] Question: Factors behind the increase in Firdapse growth guidance - Management noted the efficiency in converting diagnosed patients to treatment and the increase in RGCC tests as major contributors [43][44] Question: Impact of SUMMIT study on AGAMREE forecast - Management indicated that while the SUMMIT study is important, current guidance does not factor in potential impacts from the study [66][69] Question: Changes in AGAMREE's median age of new enrollees - Management confirmed a decrease in median age, indicating younger patients are more likely to adhere to therapy [55][58] Question: Reimbursement landscape for AGAMREE - Management reported strong reimbursement rates above 85%, with some patients facing step edits [57][58] Question: Phase 1a readout impact on AGAMREE plans - Management stated that the readout will inform lifecycle management opportunities but does not currently impact guidance [88][90]